United States Patent 9,844,537: Aceclidine Ophthalmic Composition Claims, Patent Scope, and Competitive Landscape

U.S. Patent No. 9,844,537 protects ophthalmic compositions containing aceclidine for presbyopia, with dependent claims covering mannitol, surfactants, viscosity enhancers, preservatives, defined concentration ranges, and selected treatment outcomes. Its broadest composition claim is materially narrower than a claim to aceclidine itself because it requires both aceclidine and a polyol. The strongest commercial protection is concentrated in the formulation ranges around 1.65%-1.80% aceclidine, 2.0%-3.0% polyol, and the specific 1.75% aceclidine/2.5% mannitol formulation recited in claims 11 and 15.

The patent also includes method claims for presbyopia, irregular astigmatism, keratoconic ectasia, low myopia, hyperopia and astigmatism. It does not, on the face of the supplied claims, claim an aceclidine-free formulation, a composition using aceclidine without a polyol, or every possible ophthalmic use of aceclidine.

What does U.S. Patent 9,844,537 protect?

The patent has three principal claim groups:

Claim group	Claims	Protected subject matter
Broad composition	1-10	Aceclidine at about 0.25%-2.0% w/v with a polyol, plus optional excipient classes
Narrow commercial composition	11-16	Defined aceclidine, polyol, surfactant, viscosity-enhancer, cycloplegic and excipient ranges
Treatment methods	17-19	Administration for presbyopia and specified refractive or corneal conditions

The independent composition claim, claim 1, requires:

An ophthalmological composition.
Treatment of presbyopia.
An active agent consisting of about 0.25%-2.0% w/v aceclidine.
A polyol.

The phrase “active agent consisting of” limits the active-agent component to aceclidine. It does not necessarily exclude inactive ingredients, but it creates a meaningful distinction from formulations containing a second pharmacologically active ingredient such as brimonidine, carbachol or pilocarpine.

The claim does not expressly require aceclidine hydrochloride, a particular pH, a particular dosage volume, a particular preservative system or a particular delivery device. Those limitations may appear in the specification or other family members, but they are not present in claim 1 as supplied.

How broad is claim 1?

Claim 1 is broad across several formulation variables but narrow across composition architecture.

Breadth of claim 1

Claim 1 covers, in principle:

Aceclidine concentrations from approximately 0.25% to 2.0% w/v.
Any polyol, unless limited by a construction derived from the specification.
Ophthalmic dosage forms intended to treat presbyopia.
Formulations with or without the additional excipients recited in dependent claims.

The polyol limitation is central. Mannitol is expressly claimed in claim 2, but claim 1 is not limited to mannitol. Other polyols could potentially fall within claim 1 if they meet the claim construction and are used in the claimed ophthalmic composition.

Limits of claim 1

Claim 1 does not cover:

Aceclidine above approximately 2.0% w/v.
Aceclidine below approximately 0.25% w/v.
Aceclidine without a polyol.
A composition in which another agent is part of the active-agent definition, depending on how “consisting of” is construed.
A formulation used for a non-presbyopia indication unless the claim’s treatment-purpose limitation is satisfied.

A competitor could therefore examine a formulation using aceclidine outside the claimed concentration range, omitting the polyol, or using a legally distinct active-agent structure. Each design-around would require analysis of equivalents, prosecution history and other patents in the family.

Which formulation features are protected?

The dependent claims create progressively narrower formulation positions.

Claims	Limitation	Commercial significance
2	Mannitol at about 1.0%-10.0% w/v	Protects the principal polyol identified in the claim set
3-6	Nonionic surfactant, including polysorbate 80 or polyoxyl 35 castor oil	Addresses solubility, wetting and formulation stability
7-9	Viscosity enhancer, including cellulose derivatives, hyaluronate, carbomer or gum	Covers residence time and ocular delivery characteristics
10	Benzalkonium chloride, sorbic acid, oxychloro complex or combinations	Protects preservative systems
11	1.65%-1.80% aceclidine and 2.0%-3.0% polyol	Narrow concentration window likely directed to optimized product formulations
12	2.0%-6.0% nonionic surfactant	Adds a defined surfactant range
13	0.5%-2.0% viscosity enhancer	Adds a defined rheology range
14	0.004%-0.007% cycloplegic agent	Covers a highly specific combination
15	1.75% aceclidine and 2.5% mannitol	Most specific core formulation claim
16	Sodium chloride, benzalkonium chloride, sorbate, EDTA and citric acid at listed concentrations	Protects an excipient package

The concentration terms “about,” “from about” and “approximately” generally introduce claim-construction questions rather than unlimited flexibility. Their effective scope depends on intrinsic evidence, examples, prosecution amendments and accepted measurement tolerances.

What is the strongest claim in the patent?

Claim 15 is the most commercially focused composition claim:

About 1.75% w/v aceclidine as the sole active agent and about 2.5% w/v mannitol.

Its strength comes from the combination of:

A specific aceclidine concentration.
A specific mannitol concentration.
A sole-active-agent limitation.
A formulation directed to presbyopia treatment.

Claim 18 adds a performance limitation to the claim 15 formulation: improvement in near-vision acuity by at least three lines of resolution for at least six hours. That claim may be valuable if clinical data support the limitation and if the result can be reliably measured. It is narrower than claim 15 and may be more vulnerable to disputes over clinical methodology, baseline acuity, endpoint definition and proof of the claimed duration.

How do the method-of-use claims operate?

Claims 17-19 extend protection beyond the composition itself.

Presbyopia treatment

Claim 17 covers administering the claim 1 composition to a patient in need. It is a composition-dependent method claim, so an accused product must satisfy the composition limitations incorporated through claim 1.

Claim 18 is narrower. It requires:

The claim 15 formulation.
Treatment of presbyopia.
At least three lines of near-vision improvement.
Duration of at least six hours.

The claim may be relevant to a product label, clinical protocol or promotional indication if those materials direct the claimed use. In a patent-infringement analysis, induced-infringement exposure can depend on labeling, instructions, physician practice and the availability of substantial noninfringing uses.

Other ophthalmic conditions

Claim 19 covers treatment of:

Irregular astigmatism.
Keratoconic ectasia.
Low myopia.
Hyperopia.
Hyperopia with or without astigmatism.

This claim is broader in disease scope than the presbyopia claims but still depends on use of the claim 1 composition. The listed conditions create a separate enforcement theory, especially if a product is marketed for corneal or refractive applications beyond age-related near-vision loss.

What are the likely infringement positions?

A product is most exposed when it has the following profile:

Product characteristic	Exposure under the supplied claims
Aceclidine at 1.65%-1.80% w/v	High under claim 11
Aceclidine at 1.75% w/v	High under claim 15
Mannitol at 2.0%-3.0% w/v	High under claims 11 and 15
Aceclidine plus any polyol at 0.25%-2.0%	Potential exposure under claim 1
Polysorbate 80 at 0.5%-10.0%	Potential exposure under claim 6
Viscosity enhancer at 1.0%-2.0% and 25-10,000 cP	Potential exposure under claim 9
Benzalkonium chloride, sorbate or oxychloro complex	Potential exposure under claim 10
Aceclidine outside 0.25%-2.0%	Reduced literal exposure to claim 1, subject to other claims
Aceclidine without a polyol	Reduced exposure to the supplied composition claims
Aceclidine with another active agent	Potentially reduced exposure because of “consisting of,” subject to construction

A formulation that matches the 1.75% aceclidine and 2.5% mannitol profile is the clearest literal infringement risk under the supplied claim set. Changing a concentration by a small amount may not eliminate risk where “about” applies or where the doctrine of equivalents is relevant.

When does U.S. Patent 9,844,537 lose exclusivity?

The patent issued in 2017. Its enforceable term is generally calculated under the modern patent-term rules from the earliest effective nonprovisional filing date, subject to terminal disclaimers, patent-term adjustment and any applicable patent-term extension.[1]

A reliable expiration date cannot be determined from the claims alone. Patent expiration analysis must account for:

The earliest effective nonprovisional filing date.
Continuation or divisional relationships.
Patent-term adjustment.
Terminal disclaimers.
Patent-term extension under 35 U.S.C. § 156.
Any post-grant disclaimer or lapse.

The patent should not be treated as expiring on the issue date plus 20 years. The operative date is the adjusted statutory expiration date recorded in USPTO assignment and patent records. FDA regulatory exclusivity, if applicable to an approved product, is separate from patent exclusivity.[2]

What is the Orange Book status of U.S. Patent 9,844,537?

Orange Book listing depends on an approved NDA and a patent submission by the NDA holder. A patent is not automatically listed merely because it covers a pharmaceutical composition or method of treatment. Under FDA regulations, the patent must claim the approved drug, a method of using the approved drug, or another qualifying subject matter identified in the listing rules.[3]

For an aceclidine ophthalmic product, the relevant Orange Book questions are:

Is there an approved NDA for the product?
Is the NDA holder submitting 9,844,537 to FDA?
Which claims are identified as covering the drug or approved method?
What is the listed expiration date?
Has an authorized generic or 505(b)(2) applicant made a Paragraph IV certification?

The supplied claims alone do not establish a current Orange Book listing, an NDA number, or a Paragraph IV filing. Those matters must be determined from the FDA’s current Approved Drug Products with Therapeutic Equivalence Evaluations database and patent-listing records.[3]

Which companies are challenging the patent?

No challenger, Paragraph IV certification, ANDA, 505(b)(2) application or litigation matter can be attributed to this patent from the claim text alone. A complete challenger analysis requires review of:

PACER and district-court dockets.
ANDA litigation notices under 21 U.S.C. § 355(j).
FDA Orange Book patent certifications.
USPTO Patent Center prosecution records.
Assignment and ownership records.
PTAB proceedings.
Public settlement filings.

For presbyopia products, the practical challenger universe includes generic ophthalmic manufacturers, 505(b)(2) applicants and developers of alternative miotic formulations. A competing product is not automatically a patent challenger. It may avoid the claims through a different active ingredient, concentration, excipient system, dosage form or indication.

How does this patent compare with competing presbyopia patent estates?

Aceclidine is only one part of the presbyopia landscape. Competing estates generally fall into four groups:

Technology	Typical active ingredient or platform	Main patent risk
Aceclidine ophthalmic drops	Aceclidine with polyol-based formulation	Composition, excipient and method claims
Pilocarpine products	Pilocarpine ophthalmic solution or optimized delivery system	Drug-specific formulation and dosing claims
Carbachol combinations	Carbachol, often with another active agent	Combination, safety and dosing claims
Brimonidine combinations	Brimonidine with miotic or presbyopia agents	Combination composition and method claims
Device-based approaches	Corneal implants, contact lenses or surgical systems	Device, manufacturing and procedure claims

U.S. Patent 9,844,537 is strongest against formulations that reproduce the claimed aceclidine-polyol architecture. It is less directly relevant to a pilocarpine-only product, a carbachol combination that does not contain aceclidine, or a nonpharmaceutical device.

The major competitive distinction is that aceclidine can support a product-specific formulation estate, while products based on older miotics may face a more fragmented landscape involving formulation patents, delivery systems, combination claims and method-of-use patents.

What biosimilar and generic entry risks exist?

Biosimilar risk is not the principal issue for aceclidine. Aceclidine is a small molecule, so a competing product would generally use an ANDA or, for a modified formulation or clinical development program, a 505(b)(2) pathway rather than a biosimilar application under the Public Health Service Act.[4]

The principal entry scenarios are:

ANDA generic entry

An ANDA applicant would need to address listed patents through Paragraph III or Paragraph IV certifications. A Paragraph IV certification could trigger Hatch-Waxman litigation and a potential 30-month stay if the statutory conditions are met.[5]

505(b)(2) entry

A 505(b)(2) applicant could develop a formulation with different excipients, concentrations, dosing or clinical use. Such an applicant may face listed-patent certifications and infringement litigation, but its regulatory strategy may differ from a conventional generic.

Noninfringing formulation entry

A competitor could seek to avoid the supplied claims by:

Omitting the polyol.
Using a different active agent.
Selecting aceclidine outside the claimed concentration range.
Using a different dosage form.
Avoiding a claimed indication.
Designing around the specific mannitol and excipient ranges.

The ability to avoid this patent does not establish freedom to operate because other family members or third-party patents may claim the alternative design.

What manufacturing and formulation barriers does the patent create?

The patent does not claim a manufacturing process in the supplied claims. Its barriers are formulation-based. A competing developer would need to address:

Aceclidine chemical stability in an aqueous ophthalmic environment.
Solubility and precipitation behavior.
Ocular tolerability.
Preservative compatibility.
Surfactant concentration and irritation.
Viscosity and drop delivery.
Sterility and container-closure compatibility.
pH and osmolality.
Dose uniformity during shelf life.

Mannitol, surfactants and viscosity enhancers may be selected for technical reasons independent of patent strategy. That creates design-around tension: the excipient package that provides the best clinical or manufacturing performance may also be the package most exposed to claims 2-16.

What is the commercial relevance of the patent?

The commercial value depends on whether an approved product uses the claimed formulation. If a marketed aceclidine product uses approximately 1.75% aceclidine and 2.5% mannitol, claim 15 is potentially a core product claim. Claims 11-16 could provide fallback positions if broader claims are narrowed or challenged.

Revenue exposure is therefore concentrated in the product’s U.S. sales during the period in which:

The patent remains enforceable.
The approved formulation falls within the claims.
The patent is listed or otherwise enforceable against the relevant entrant.
No invalidity, noninfringement or prosecution-history defense defeats enforcement.
No settlement permits earlier entry.

A revenue model should distinguish patent expiry from regulatory exclusivity, pediatric exclusivity, litigation stays and settlement-based launch dates. FDA approval alone does not establish the patent’s remaining market life.[2]

How strong is the patent estate based on the supplied claims?

The supplied patent has a layered claim structure:

Claim 1 provides the broadest composition position.
Claims 2-10 add conventional formulation components.
Claims 11-16 target defined commercial formulations.
Claims 17-19 add treatment-use protection.

That structure improves enforcement flexibility. If a broad claim is challenged, the narrower formulation claims may remain relevant to a commercial product. The principal validity pressure points are likely to include:

Written description and enablement across the full concentration and polyol ranges.
Obviousness over prior aceclidine ophthalmic compositions.
Definiteness of “about,” “initial viscosity” and clinical performance terms.
Support for the broad disease scope in claim 19.
Claim construction of “active agent consisting of.”
Patent-term and terminal-disclaimer issues.

The patent is more commercially robust when the marketed product closely matches claims 11 and 15 than when it relies only on the broad “aceclidine plus polyol” language in claim 1.

Key Takeaways

U.S. Patent 9,844,537 is directed to aceclidine ophthalmic compositions for presbyopia and related refractive or corneal conditions.
Claim 1 requires aceclidine at about 0.25%-2.0% w/v plus a polyol.
Claims 11 and 15 are the most commercially important because they target narrow aceclidine and mannitol concentration combinations.
Claim 15 specifically covers about 1.75% aceclidine as the sole active agent with about 2.5% mannitol.
Claims 3-10 and 12-16 cover surfactants, viscosity enhancers, preservatives, cycloplegics and defined excipient ranges.
Claim 18 adds a three-line, six-hour near-vision performance limitation.
Generic or 505(b)(2) entry would likely require a Paragraph III or Paragraph IV strategy if the patent is listed for an approved product.
Aceclidine is a small molecule, so biosimilar approval is generally not the relevant competitive pathway.
The patent’s expiration date, Orange Book status, ownership and litigation history require review of current USPTO, FDA and court records rather than claim-text analysis alone.

FAQs

Can a competitor avoid U.S. Patent 9,844,537 by using aceclidine without mannitol?

Potentially. Claim 1 requires a polyol, while mannitol is only one expressly claimed polyol. A formulation with aceclidine and no polyol would face reduced literal exposure to the supplied composition claims, subject to other patent claims and equivalents analysis.

Does claim 15 cover every 1.75% aceclidine eye drop?

No. Claim 15 also requires about 2.5% w/v mannitol and aceclidine as the sole active agent. A 1.75% aceclidine product lacking mannitol would not satisfy the full claim as supplied.

Can a product containing aceclidine and brimonidine infringe these claims?

The “active agent consisting of” language may limit the claim to aceclidine as the active agent. The answer depends on claim construction, whether brimonidine is treated as an active agent in the accused formulation, and whether other patent claims cover the combination.

Does FDA approval automatically extend the patent term?

No. FDA approval and patent term are separate systems. A qualifying patent-term extension under 35 U.S.C. § 156 is distinct from regulatory exclusivity and must be confirmed in the patent record.

Is a competing aceclidine product automatically a patent challenger?

No. A competitor may avoid the claims through formulation design, indication, concentration or regulatory pathway. A formal patent challenge requires a Paragraph IV certification, litigation, PTAB proceeding or another documented validity or enforceability action.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation. https://www.uspto.gov/patents/laws/patent-term-adjustment
U.S. Food and Drug Administration. (n.d.). Regulatory exclusivity. https://www.fda.gov/drugs/development-approval-process-drugs/drug-competition-and-patent-term-restoration-act-hatch-waxman-amendments
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilar-and-interchangeable-products
21 U.S.C. § 355. New drugs. https://www.govinfo.gov/content/pkg/USCODE-2023-title21/html/USCODE-2023-title21-chap9-subchapV-partA-sec355.htm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			TREATMENT OF PRESBYOPIA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014311558	⤷ Start Trial
Australia	2016280615	⤷ Start Trial
Australia	2016280616	⤷ Start Trial
Australia	2019200623	⤷ Start Trial
Brazil	112017025722	⤷ Start Trial
Brazil	112017025726	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,844,537

Which drugs does patent 9,844,537 protect, and when does it expire?

Summary for Patent: 9,844,537